Trial
NCT05418673
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
Denali Therapeutics Inc.
Condition
Parkinson Disease
Intervention
BIIB122
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-26